雙成藥業(002693.SZ)半年度淨虧損1456.05萬元
格隆匯8月15日丨雙成藥業(002693.SZ)發佈2019年半年度報告,實現營業收入1.78億元,同比增長0.60%;歸屬於上市公司股東的淨虧損1456.05萬元,同比收窄22.58%;基本每股虧損0.04元。
報告期內,公司研發投入1873.51元,佔營業收入的10.54%。經過多年的艱苦努力,已建成具有國際研發註冊和專利挑戰能力、集多肽原料藥與製劑仿製藥開發為一體、研發技術隊伍梯隊較為完整的研發體系。在高水平引路人的帶領、研發團隊不懈努力和生產質量等各部門的緊密配合下,報告期內,在研項目穩步推進,2019年1月獲得國家藥品監督管理局批准簽發的“注射用比伐蘆定”《藥品註冊批件》,並已提交了一致性評價申請;公司對注射用比伐蘆定在美國專利挑戰成功,並向FDA遞交了正式批准申請;注射用胸腺法新一致性評價申請已於2018年上半年遞交;生長抑素原料藥工藝優化已完成,注射用生長抑素的一致性評價研發已在進行中;注射用泮托拉唑鈉已基本完成一致性評價研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.